Zobrazeno 1 - 10
of 10
pro vyhledávání: '"José I Fernández-Montequín"'
Publikováno v:
Biotecnología Aplicada, Vol 27, Iss 2, Pp 165-170
Fourteen patients having diabetic foot ulcers on their limbs and who received amputation criteria at certain degree were included in this study, giving their consent to be treated. They were subjected to traditional medical-dietary and hygienic medic
Externí odkaz:
https://doaj.org/article/62feb4de5f1d4146bc8a5c5f9b0eec83
Autor:
Ariana García-Ojalvo, Jorge Berlanga-Acosta, José I Fernández-Montequín, Eulogio Pimentel-Vazquez, Calixto Valdés-Pérez, Héctor Pérez-Saad, Gerardo Guillén-Nieto, Diana García del Barco-Herrera, Yssel Mendoza-Marí, Moshe Kulikovsky, Aleida Urquiza-Rodríguez, Viviana Falcón-Cama, William Savigne-Gutierrez, Maday Fernández-Mayola
Publikováno v:
BioMed Research International, Vol 2017 (2017)
BioMed Research International
BioMed Research International
Soon after epidermal growth factor (EGF) discovery, somein vivomodels appeared demonstrating its property to enhance cutaneous wound healing. EGF was the first growth factor (GF) introduced in the clinical arena as a healing enhancer, exerting its mi
Autor:
Carmen M Valenzuela-Silva, Elizeth García-Iglesias, José I Fernández-Montequín, Amaurys del Río-Martín, Isis Belkis Yera Alos, Ángela D. Tuero-Iglesias, Odalys González-Díaz, Pedro Lopez-Saura
Publikováno v:
Diabetes Care
OBJECTIVE To determine if partial wound closure surrogate markers proposed for neuropathic, small diabetic foot ulcers (DFUs) can be extended to advanced lesions and if the development of granulation tissue can be used to predict complete healing. RE
Autor:
Odalys González Díaz, Heriberto Artaza-Sanz, José I Fernández-Montequín, Carlos M Hernández-Cañete, Pedro Lopez-Saura, William Savigne, Carmen M Valenzuela-Silva, Fidel Rivero-Fernández, Natasha Sancho-Soutelo, Pablo Sánchez-Penton, Lourdes Morejón-Vega, Cecilio González-Benavides, Alberto Vázquez-Proenza, Arístides García-Herrera, Jorge Berlanga-Acosta
Publikováno v:
Int Wound J
Fernández‐Montequín JI, Valenzuela‐Silva CM, González Díaz O, Savigne W, Sancho‐Soutelo N, Rivero‐Fernández F, Sánchez‐Penton P, Morejón‐Vega L, Artaza‐Sanz H, García‐Herrera A, González‐Benavides C, Hernández‐Cañete CM
Autor:
Ernesto L Mola, Sergio Bermúdez-Rojas, Felix Rosales, Blas Y Betancourt, Mayte Ramírez-Navas, Elizeth García-Iglesias, Gisselle Leyva-Gonzalez, José I Fernández-Montequín, Luis H Martinez, Jorge Berlanga-Acosta, Marianela Garcia-Siverio, Katia Galán-Naranjo, Ricardo Silva-Rodriguez
Publikováno v:
Int Wound J
Previous studies have shown that an epidermal growth factor-based formulation (Heberprot-P) can enhance granulation of high-grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to compl
Autor:
Neobalis Franco, Calixto Valdez, Luis Javier Herrera, Gerardo Guillén, William Savigne, José I Fernández-Montequín, Amaurys del Río, José Suárez Alba, Pedro Lopez-Saura, Ernesto López, Jorge Berlanga Acosta
Publikováno v:
Int Wound J
This study examined if a series of epidermal growth factor (EGF) local infiltrations can enhance the healing process of complicated diabetic wounds. Twenty-nine in-hospital patients with diabetic neuropathic or ischaemic lesions with high risk of amp
Autor:
Odalys González-Díaz, José I Fernández-Montequín, Pedro Lopez-Saura, Ernesto López-Mola, Luis Herrera-Martínez, Boris Acevedo-Castro, Isis B Yera-Alos, Amaurys del Río-Martín, Jorge Berlanga-Acosta, Carmen M Valenzuela-Silva
Publikováno v:
Advances in Pharmacoepidemiology & Drug Safety.
The intralesional injection of recombinant human epidermal growth factor (rhEGF) has been recently approved and introduced in several countries for the treatment of advanced diabetic foot ulcers (DFU), based on the results of five exploratory and one
Autor:
Héctor Alvarez, Duarte, José I, Fernández Montequín, Martha M, Fors López, José Hernández, Carretero, Miriam Mahia, Vilas, Milagros García, Mesa
Publikováno v:
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. 16(2)
De Marco Formula (DMF) is a novel formulation of procaine and PVP.To assess the efficacy and safety of DMF as an adjunctive therapy for infected ischemic diabetic foot in a prospective randomized controlled clinical trial.Adult patients, 39 male/ 79
Autor:
Carmen M Valenzuela-Silva, Elizeth García-Iglesias, Neobalis Franco-Pérez, William Savigne-Gutierrez, Pedro Lopez-Saura, Lourdes Morejón-Vega, Heriberto Artaza-Sanz, Cecilio González-Benavides, Blas Y Betancourt, José I Fernández-Montequín, Ricardo Silva-Rodriguez, Ena Infante-Cristiá, Jorge Berlanga-Acosta, Osvaldo Eliseo-Musenden
Publikováno v:
Int Wound J
To investigate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in advanced diabetic foot ulcers (DFU) A double-blind trial was carried out to test two rhEGF dose levels in type 1 or 2 diabetes patients with Wagner's grade
Publikováno v:
Biotecnología Aplicada, Vol 27, Iss 2, Pp 165-170
Fourteen patients having diabetic foot ulcers on their limbs and who received amputation criteria at certain degree were included in this study, giving their consent to be treated. They were subjected to traditional medical-dietary and hygienic medic